Skip to main content
SpringerLink
Log in

Intermediate Uveitis

  • Living reference work entry
  • First Online:
Albert and Jakobiec's Principles and Practice of Ophthalmology

Abstract

Intermediate uveitis is a major anatomic category of uveitis with predominantly vitreous inflammation [1]. Systemic illnesses such as sarcoidosis and MS may be present, and infections or neoplasia can masquerade as intermediate uveitis. The classic undifferentiated form is pars planitis, which is identified by characteristic exudates overlying the peripheral retina and pars plana without evidence of systemic disease. Retinal vasculitis and macular edema are common accompaniments of vitreous inflammation. There is a worldwide incidence, and all age groups and both genders are affected.

Patients with mild disease were often observed without treatment in the past. Both medical and surgical therapies are now employed for a wider range of disease. Medical therapies are standard ones used in the treatment of all uveitis, but surgical therapy with cryoretinopexy, panretinal photocoagulation, or vitrectomy is relatively specific for intermediate uveitis and may lead to remission in some cases. Control of cystoid macular edema (CME) is probably the most common factor in determining long-term visual outcome. Normal or near-normal vision is an attainable goal in almost all cases, but achieving this may require consultation with a subspecialist ophthalmologist experienced in the management of uveitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.

    PubMed  Google Scholar 

  2. Lai FH, Liu DT, Lam DS. Review of intermediate uveitis. Asia Pac J Ophthalmol (Phila). 2013;2(6):375–87.

    Google Scholar 

  3. Davis JL. Intermediate uveitis. In: Albert DM, Miller JW, Azar DT, Blodi B, editors. Albert & Jakobiec’s principles of ophthalmology. 3rd ed. London: Elsevier Saunders; 2007. p. 1161–72.

    Google Scholar 

  4. Ozdal PC, Berker N, Tugal-Tutkun I. Pars planitis: epidemiology, clinical characteristics, management and visual prognosis. J Ophthalmic Vis Res. 2015;10(4):469–80.

    PubMed  PubMed Central  Google Scholar 

  5. Babu BM, Rathinam SR. Intermediate uveitis. Indian J Ophthalmol. 2010;58(1):21–7.

    PubMed  Google Scholar 

  6. Ness T, Boehringer D, Heinzelmann S. Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. Orphanet J Rare Dis. 2017;12(1):81.

    PubMed  PubMed Central  Google Scholar 

  7. de Boer J, Berendschot TT, van der Does P, Rothova A. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol. 2006;141(4):616–21.

    PubMed  Google Scholar 

  8. Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144(6):812–7.

    PubMed  Google Scholar 

  9. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kacmaz RO, Levy-Clarke GA, et al. Remission of intermediate uveitis: incidence and predictive factors. Am J Ophthalmol. 2016;164:110–117.e2.

    PubMed  PubMed Central  Google Scholar 

  10. Kalinina Ayuso V, ten Cate HA, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. 2011;95(5):646–51.

    Article  CAS  PubMed  Google Scholar 

  11. Vidovic-Valentincic N, Kraut A, Hawlina M, Stunf S, Rothova A. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol. 2009;93(4):477–80.

    Article  CAS  PubMed  Google Scholar 

  12. Annamalai R, Biswas J. Patterns of intermediate uveitis in children presenting at a Tertiary Eye Care Center in South India. Middle East Afr J Ophthalmol. 2017;24(2):94–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Arellanes-Garcia L, Navarro-Lopez L, Recillas-Gispert C. Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm. 2003;11(1):53–60.

    Article  PubMed  Google Scholar 

  14. Paroli MP, Spinucci G, Monte R, Pesci FR, Abicca I, Pivetti PP. Intermediate uveitis in a pediatric Italian population. Ocul Immunol Inflamm. 2011;19(5):321–6.

    Article  PubMed  Google Scholar 

  15. Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44(5):288–93.

    Article  PubMed  Google Scholar 

  16. Venkatesh P, Gogia V, Shah B, Gupta S, Sagar P, Garg S. Patterns of uveitis at the Apex Institute for Eye Care in India: results from a prospectively enrolled patient data base (2011–2013). Int Ophthalmol. 2016;36(3):365–72.

    Article  PubMed  Google Scholar 

  17. Luca C, Raffaella A, Sylvia M, Valentina M, Fabiana V, Marco C, et al. Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases. Int Ophthalmol. 2018;38(1):133–42.

    PubMed  Google Scholar 

  18. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–17.

    Article  PubMed  Google Scholar 

  19. Mi H, Ho SL, Lim WK, Wong EP, Teoh SC. Trends in patterns of intermediate uveitis in a tertiary institution in Singapore. PLoS One. 2014;9(3):e91533.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, et al. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol. 2016;134(11):1237–45.

    Article  PubMed  Google Scholar 

  21. Dajee KP, Rossen JL, Bratton ML, Whitson JT, He YG. A 10-year review of pediatric uveitis at a Hispanic-dominated tertiary pediatric ophthalmic clinic. Clin Ophthalmol (Auckland, NZ). 2016;10:1607–12.

    Article  Google Scholar 

  22. Rahimi M, Oustad M, Ashrafi A. Demographic and clinical features of pediatric uveitis at a Tertiary Referral Center in Iran. Middle East Afr J Ophthalmol. 2016;23(3):237–40.

    PubMed  PubMed Central  Google Scholar 

  23. Ganesh SK, Bala A, Biswas J, Ahmed AS, Kempen JH. Pattern of pediatric uveitis seen at a Tertiary Referral Center from India. Ocul Immunol Inflamm. 2016;24(4):402–9.

    Article  PubMed  Google Scholar 

  24. Jabs DA, Dick A, Doucette JT, Gupta A, Lightman S, McCluskey P, et al. Interobserver agreement among uveitis experts on uveitic diagnoses: the standardization of uveitis nomenclature experience. Am J Ophthalmol. 2018;186:19–24.

    Article  PubMed  Google Scholar 

  25. Nikkhah H, Ramezani A, Ahmadieh H, Soheilian M, Azarmina M, Dehghan MH, et al. Childhood pars planitis; clinical features and outcomes. J Ophthalmic Vis Res. 2011;6(4):249–54.

    PubMed  PubMed Central  Google Scholar 

  26. Alaez C, Arellanes L, Vazquez A, Flores H, Navarro P, Vazquez-Garcia M, et al. Classic pars planitis: strong correlation of class II genes with gender and some clinical features in Mexican Mestizos. Hum Immunol. 2003;64(10):965–72.

    Article  CAS  PubMed  Google Scholar 

  27. Paroli MP, Abicca I, Sapia A, Bruschi S, Pivetti PP. Intermediate uveitis: comparison between childhood-onset and adult-onset disease. Eur J Ophthalmol. 2014;24(1):94–100.

    Article  PubMed  Google Scholar 

  28. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500; discussion.

    Article  PubMed  Google Scholar 

  29. Wetzig RP, Chan CC, Nussenblatt RB, Palestine AG, Mazur DO, Mittal KK. Clinical and immunopathological studies of pars planitis in a family. Br J Ophthalmol. 1988;72(1):5–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee AG. Familial pars planitis. Ophthalmic Genet. 1995;16(1):17–9.

    CAS  PubMed  Google Scholar 

  31. de-la-Torre A, Silva-Aldana CT, Munoz-Ortiz J, Pineros-Hernandez LB, Otero O, Dominguez A, et al. Uveitis and multiple sclerosis: potential common causal mutations. Mol Neurobiol. 2019;56:8008.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Greiner KH, Wilson DW, Thomson J, Kilmartin DJ, Urbaniak SJ, Forrester JV. Genetic polymorphism of HLA DR in a Scottish population of patients with pars planitis. Eur J Ophthalmol. 2003;13(5):433–8.

    CAS  PubMed  Google Scholar 

  33. Malinowski SM, Pulido JS, Goeken NE, Brown CK, Folk JC. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology. 1993;100(8):1199–205.

    CAS  PubMed  Google Scholar 

  34. Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ. The association of HLA class II with pars planitis. Am J Ophthalmol. 2001;131(5):657–9.

    CAS  PubMed  Google Scholar 

  35. Raja SC, Jabs DA, Dunn JP, Fekrat S, Machan CH, Marsh MJ, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999;106(3):594–9.

    CAS  PubMed  Google Scholar 

  36. Petrushkin H, Thomas D, Vaughan R, Kondeatis E, Stanford MR, Edelsten C, et al. Possession of the HLA-DRB1*1501 allele and visual outcome in idiopathic intermediate uveitis. JAMA Ophthalmol. 2015;133(4):482–3.

    PubMed  Google Scholar 

  37. Mantrana-Bermejo ME, Rueda-Rueda T, Bernabeu-Wittel J, Gonzalez-Escribano F, Garcia-Hernandez F, Sanchez-Roman J. [Clinical and epidemiological features and HLA association in patients with pars planitis]. Med Clin. 2010;135(5):205–8.

    Google Scholar 

  38. Marquez A, Cordero-Coma M, Martin-Villa JM, Gorrono-Echebarria MB, Blanco R, Diaz Valle D, et al. New insights into the genetic component of non-infectious uveitis through an immunochip strategy. J Med Genet. 2017;54(1):38–46.

    CAS  PubMed  Google Scholar 

  39. Atan D, Heissigerova J, Kuffova L, Hogan A, Kilmartin DJ, Forrester JV, et al. Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis. Mol Vis. 2013;19:184–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ewald L, Beate LW, Stephanie S, Wilfried R, El-Shabrawi Y. Analysis of a functional IL-6 gene polymorphism in HLAB27 associated and intermediate uveitis gives new insight in disease pathogenesis and commonality with other autoimmune diseases. J Immunol Res. 2015;2015:174062.

    PubMed  PubMed Central  Google Scholar 

  41. Lindner E, Weger M, Ardjomand N, Renner W, El-Shabrawi Y. Associations of independent IL2RA gene variants with intermediate uveitis. PLoS One. 2015;10(7):e0130737.

    PubMed  PubMed Central  Google Scholar 

  42. Lindner E, Weger M, Steinwender G, Griesbacher A, Posch U, Ulrich S, et al. IL2RA gene polymorphism rs2104286 A>G seen in multiple sclerosis is associated with intermediate uveitis: possible parallel pathways? Invest Ophthalmol Vis Sci. 2011;52(11):8295–9.

    CAS  PubMed  Google Scholar 

  43. Sarny S, Lindner E, El-Shabrawi Y. IL-23 gene in intermediate and HLA-B27-associated uveitis. Acta Ophthalmol. 2016;94(7):e662–e3.

    CAS  PubMed  Google Scholar 

  44. Yang MM, Wang J, Dong L, Kong J, Teng Y, Liu P, et al. Lack of association of C3 gene with uveitis: additional insights into the genetic profile of uveitis regarding complement pathway genes. Sci Rep. 2017;7(1):879.

    PubMed  PubMed Central  Google Scholar 

  45. Yang MM, Lai TY, Tam PO, Chiang SW, Chan CK, Luk FO, et al. Complement factor H and interleukin gene polymorphisms in patients with non-infectious intermediate and posterior uveitis. Mol Vis. 2012;18:1865–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Stanford MR, Vaughan RW, Kondeatis E, Chen Y, Edelsten CE, Graham EM, et al. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom? Br J Ophthalmol. 2005;89(8):1013–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Du L, Kijlstra A, Yang P. Immune response genes in uveitis. Ocul Immunol Inflamm. 2009;17(4):249–56.

    CAS  PubMed  Google Scholar 

  48. Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117(3):585–90.

    PubMed  Google Scholar 

  49. Yuen BG, Tham VM, Browne EN, Weinrib R, Borkar DS, Parker JV, et al. Association between smoking and uveitis: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2015;122(6):1257–61.

    PubMed  PubMed Central  Google Scholar 

  50. Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145(5):841–6.

    PubMed  PubMed Central  Google Scholar 

  51. Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57.

    PubMed  PubMed Central  Google Scholar 

  52. Breeveld J, Rothova A, Kuiper H. Intermediate uveitis and Lyme borreliosis. Br J Ophthalmol. 1992;76(3):181–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Huppertz HI, Munchmeier D, Lieb W. Ocular manifestations in children and adolescents with Lyme arthritis. Br J Ophthalmol. 1999;83(10):1149–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Matsuo T, Itami M. Seropositivity of human herpesvirus-8 in patients with uveitis. Ocul Immunol Inflamm. 2002;10(3):197–9.

    PubMed  Google Scholar 

  55. Takahashi T, Takase H, Urano T, Sugita S, Miyata K, Miyata N, et al. Clinical features of human T-lymphotropic virus type 1 uveitis: a long-term follow-up. Ocul Immunol Inflamm. 2000;8(4):235–41.

    CAS  PubMed  Google Scholar 

  56. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52(1):179–81.

    CAS  PubMed  Google Scholar 

  57. Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12(2):137–42.

    PubMed  Google Scholar 

  58. Lin J, Chen RWS, Hazan A, Weiss M. Chikungunya virus infection manifesting as intermediate uveitis. Ocul Immunol Inflamm. 2018;26(5):680–2.

    PubMed  Google Scholar 

  59. Sungur G, Hazirolan D, Bilgin G. Pattern of ocular findings in patients with biopsy-proven sarcoidosis in Turkey. Ocul Immunol Inflamm. 2013;21(6):455–61.

    PubMed  Google Scholar 

  60. Kirsch O, Frau E, Nodarian M, Labetoulle M, Offret H. [Clinical course of ocular sarcoidosis in patients with histologically proven systemic sarcoidosis]. J Fr Ophtalmol. 2001;24(6):623–7.

    Google Scholar 

  61. Hassenstein A, Bialasiewicz AA, Knospe V, Richard G. [Incidence of ocular manifestations in patients with histologically confirmed systemic sarcoidosis]. Klin Monbl Augenheilkd. 2003;220(6):414–7.

    Google Scholar 

  62. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9(2):93–102.

    CAS  PubMed  Google Scholar 

  63. Yoser SL, Forster DJ, Rao NA. Pathology of intermediate uveitis. Dev Ophthalmol. 1992;23:60–70.

    CAS  PubMed  Google Scholar 

  64. Green WR, Kincaid MC, Michels RG, Pederson JE, Kenyon KR, Maumenee AE. Pars planitis. Trans Ophthalmol Soc U K. 1981;101(Pt 3 (3)):361–7.

    PubMed  Google Scholar 

  65. Brockhurst RJ, Schepens CL, Okamura ID. Uveitis. II. Peripheral uveitis: clinical description, complications and differential diagnosis. Am J Ophthalmol. 1960;49:1257–66.

    CAS  PubMed  Google Scholar 

  66. Eichenbaum JW, Friedman AH, Mamelok AE. A clinical and histopathological review of intermediate uveitis (“pars planitis”). Bull N Y Acad Med. 1988;64(2):164–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Abu El-Asrar AM, Geboes K. An immunohistochemical study of the ‘snowbank’ in a case of pars planiti. Ocul Immunol Inflamm. 2002;10(2):117–23.

    PubMed  Google Scholar 

  68. Przezdziecka-Dolyk J, Wegrzyn A, Turno-Krecicka A, Misiuk-Hojlo M. Immunopathogenic background of pars planitis. Arch Immunol Ther Exp. 2016;64(2):127–37.

    CAS  Google Scholar 

  69. Muhaya M, Calder VL, Towler HM, Jolly G, McLauchlan M, Lightman S. Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man. Clin Exp Immunol. 1999;116(3):410–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Nolle B. Antiretinal autoantibodies in intermediate uveitis. Dev Ophthalmol. 1992;23:94–8.

    CAS  PubMed  Google Scholar 

  71. de Smet MD, Yamamoto JH, Mochizuki M, Gery I, Singh VK, Shinohara T, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol. 1990;110(2):135–42.

    PubMed  Google Scholar 

  72. Davis JL, Chan CC, Nussenblatt RB. Immunology of intermediate uveitis. Dev Ophthalmol. 1992;23:71–85.

    CAS  PubMed  Google Scholar 

  73. Bora NS, Bora PS, Kaplan HJ. Identification, quantitation, and purification of a 36 kDa circulating protein associated with active pars planitis. Invest Ophthalmol Vis Sci. 1996;37(9):1870–6.

    CAS  PubMed  Google Scholar 

  74. Bora NS, Bora PS, Tandhasetti MT, Cirrito TP, Kaplan HJ. Molecular cloning, sequencing, and expression of the 36 kDa protein present in pars planitis. Sequence homology with yeast nucleopore complex protein. Invest Ophthalmol Vis Sci. 1996;37(9):1877–83.

    CAS  PubMed  Google Scholar 

  75. Klok AM, Luyendijk L, Zaal MJ, Rothova A, Hack CE, Kijlstra A. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol. 1998;82(8):871–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm. 2001;9(2):85–92.

    PubMed  Google Scholar 

  77. Cancino-Diaz JC, Vargas-Rodriguez L, Grinberg-Zylberbaum N, Reyes-Lopez MA, Dominguez-Lopez ML, Pablo-Velazquez A, et al. High levels of IgG class antibodies to recombinant HSP60 kDa of Yersinia enterocolitica in sera of patients with uveitis. Br J Ophthalmol. 2004;88(2):247–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Castaneda-Sanchez JI, Curiel-Quesada E, Pedrosa-Seres M, Cancino-Diaz ME, Rodriguez-Martinez S, Cancino-Diaz JC. Peptidic sequence “HSEAETGPP” is recognized by the sera of pars planitis patients. Clin Invest Med. 2009;32(3):E206–11.

    CAS  PubMed  Google Scholar 

  79. Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201.

    CAS  PubMed  Google Scholar 

  80. Kwon JW, Sim Y, Jee D. Association between intermediate uveitis and toxocariasis in the Korean population. Medicine. 2017;96(5):e5829.

    PubMed  PubMed Central  Google Scholar 

  81. Sancho L, Kramer M, Koriat A, Eiger-Moscovich M, Sharon Y, Amer R. Complications in intermediate uveitis: prevalence, time of onset, and effects on vision in short-term and long-term follow-up. Ocul Immunol Inflamm. 2019;27(3):447–55.

    PubMed  Google Scholar 

  82. Maris K, Van Calster J, Wouters C, Casteels I. Clinical symptoms and complications of pars planitis in childhood. Bull Soc Belge Ophtalmol. 2005;295:29–33.

    Google Scholar 

  83. Hogan MJ, Kimura SJ, O’Connor GR. Peripheral retinitis and chronic cyclitis in children. Trans Ophthalmol Soc U K. 1965;85:39–52.

    CAS  PubMed  Google Scholar 

  84. Smith RE, Godfrey WA, Kimura SJ. Complications of chronic cyclitis. Am J Ophthalmol. 1976;82(2):277–82.

    CAS  PubMed  Google Scholar 

  85. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–306.

    PubMed  Google Scholar 

  86. Khodadoust AA, Karnama Y, Stoessel KM, Puklin JE. Pars planitis and autoimmune endotheliopathy. Am J Ophthalmol. 1986;102(5):633–9.

    CAS  PubMed  Google Scholar 

  87. Welch RB, Maumenee AE, Wahlen HE. Peripheral posterior segment inflammation, vitreous opacities, and edema of the posterior pole. Arch Ophthalmol. 1960;64:540–9.

    CAS  PubMed  Google Scholar 

  88. Bec P, Arne JL, Philippot V, Secheyron P, Bezombes JM. [Basal uveo-retinitis (peripheral uveitis, chronic posterior cyclitis, pars planitis, vitritis, hyalo-retinitis) and other inflammations of the peripheral retina]. Arch Ophtalmol. 1977;37(3):169–96.

    Google Scholar 

  89. Belfort R Jr, Nussenblatt RB, Lottemberg C, Kwitko S, Chamon W, de Smet M, et al. Spontaneous lens subluxation in uveitis. Am J Ophthalmol. 1990;110(6):714–6.

    PubMed  Google Scholar 

  90. Berker N, Sen E, Elgin U, Atilgan CU, Dursun E, Yilmazbas P. Analysis of clinical features and visual outcomes of pars planitis. Int Ophthalmol. 2018;38(2):727–36.

    PubMed  Google Scholar 

  91. Madow B, Galor A, Feuer WJ, Altaweel MM, Davis JL. Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol. 2011;152(2):170–6.e1.

    PubMed  PubMed Central  Google Scholar 

  92. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–71.

    CAS  PubMed  Google Scholar 

  93. Suh DW, Pulido JS, Jampol LM, Chong LP, Thomas M. Coats’-like response in pars planitis. Retina (Philadelphia, Pa). 1999;19(1):79–80.

    CAS  Google Scholar 

  94. Chen PP, Chong LP. Coats’-like response in a patient with pars planitis. Br J Ophthalmol. 1996;80(7):675–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121(2):588–595.e1.

    PubMed  Google Scholar 

  96. Pederson JE, Kenyon KR, Green WR, Maumenee AE. Pathology of pars planitis. Am J Ophthalmol. 1978;86(6):762–74.

    CAS  PubMed  Google Scholar 

  97. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100(6):818–24; discussion 25.

    CAS  PubMed  Google Scholar 

  98. Kimura SJ, Hogan MJ. Chronic cyclitis. Trans Am Ophthalmol Soc. 1963;61:397–417.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Lauer AK, Smith JR, Robertson JE, Rosenbaum JT. Vitreous hemorrhage is a common complication of pediatric pars planitis. Ophthalmology. 2002;109(1):95–8.

    PubMed  Google Scholar 

  100. Felder KS, Brockhurst RJ. Neovascular fundus abnormalities in peripheral uveitis. Arch Ophthalmol. 1982;100(5):750–4.

    Article  CAS  PubMed  Google Scholar 

  101. Deane JS, Rosenthal AR. Course and complications of intermediate uveitis. Acta Ophthalmol Scand. 1997;75(1):82–4.

    Article  CAS  PubMed  Google Scholar 

  102. Niederer RL, Sharief L, Bar A, Lightman SL, Tomkins-Netzer O. Predictors of long-term visual outcome in intermediate uveitis. Ophthalmology. 2017;124(3):393–8.

    Article  PubMed  Google Scholar 

  103. Gritz DC, Schwaber EJ, Wong IG. Complications of uveitis: the Northern California Epidemiology of Uveitis Study. Ocul Immunol Inflamm. 2018;26(4):584–94.

    PubMed  Google Scholar 

  104. Eiger-Moscovich M, Tomkins-Netzer O, Amer R, Habot-Wilner Z, Kasb A, Friling R, et al. Visual and clinical outcome of macular edema complicating pediatric noninfectious uveitis. Am J Ophthalmol. 2019;202:72–8.

    Article  PubMed  Google Scholar 

  105. Chester GH, Blach RK, Cleary PE. Inflammation in the region of the vitreous base. Pars planitis. Trans Ophthalmol Soc U K. 1976;96(1):151–7.

    CAS  PubMed  Google Scholar 

  106. Pruett RC, Brockhurst J, Letts NF. Fluorescein angiography of peripheral uveitis. Am J Ophthalmol. 1974;77(4):448–53.

    Article  CAS  PubMed  Google Scholar 

  107. Gupta S, Shah DN, Joshi SN, Aryal M, Puri LR. Patterns of macular edema in uveitis as diagnosed by optical coherence tomography in Tertiary Eye Center. Nepal J Ophthalmol. 2018;10(19):39–46.

    Article  PubMed  Google Scholar 

  108. Gehl Z, Kulcsar K, Kiss HJ, Nemeth J, Maneschg OA, Resch MD. Retinal and choroidal thickness measurements using spectral domain optical coherence tomography in anterior and intermediate uveitis. BMC Ophthalmol. 2014;14:103.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, et al. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology. 2013;120(9):1852–9.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Kim BH, Shin JY, Yu HG. Discrepancy in fluorescein angiography and optical coherence tomography findings of macular edema in intermediate uveitis. Ocul Immunol Inflamm. 2016;24(6):653–9.

    Article  PubMed  Google Scholar 

  111. Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, et al. The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm. 2012;20(3):171–81.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Nicholson BP, Zhou M, Rostamizadeh M, Mehta P, Agron E, Wong W, et al. Epidemiology of epiretinal membrane in a large cohort of patients with uveitis. Ophthalmology. 2014;121(12):2393–8.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Salcedo-Villanueva G, Arellanes-Garcia L, Fromow-Guerra J, Hernandez-Quintela E. [Association of epiretinal membranes with macular edema in pars planitis]. Arch Soc Esp Oftalmol. 2014;89(1):22–6.

    Google Scholar 

  114. Tsui I, Kaines A, Schwartz S. Patterns of periphlebitis in intermediate uveitis using ultra wide field fluorescein angiography. Semin Ophthalmol. 2009;24(1):29–33.

    Article  PubMed  Google Scholar 

  115. Laovirojjanakul W, Acharya N, Gonzales JA. Ultra-widefield fluorescein angiography in intermediate uveitis. Ocul Immunol Inflamm. 2019;27(3):356–61.

    Article  PubMed  Google Scholar 

  116. Tian M, Tappeiner C, Zinkernagel MS, Huf W, Wolf S, Munk MR. Evaluation of vascular changes in intermediate uveitis and retinal vasculitis using swept-source wide-field optical coherence tomography angiography. Br J Ophthalmol. 2018;103:1289.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Kalina PH, Pach JM, Buettner H, Robertson DM. Neovascularization of the disc in pars planitis. Retina (Philadelphia, Pa). 1990;10(4):269–73.

    Article  CAS  Google Scholar 

  118. Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, et al. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156(3):468–77.e2.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Patel AK, Newcomb CW, Liesegang TL, Pujari SS, Suhler EB, Thorne JE, et al. Risk of retinal neovascularization in cases of uveitis. Ophthalmology. 2016;123(3):646–54.

    Article  PubMed  Google Scholar 

  120. Tian M, Tappeiner C, Zinkernagel MS, Wolf S, Munk MR. Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis. Acta Ophthalmol. 2019;97:e785.

    Article  CAS  PubMed  Google Scholar 

  121. Brockhurst RJ, Schepens CL. Uveitis. IV. Peripheral uveitis: the complications of retinal detachment. Arch Ophthalmol. 1968;80(6):747–53.

    Article  CAS  PubMed  Google Scholar 

  122. Pollack AL, McDonald HR, Johnson RN, Ai E, Irvine AR, Lahey JM, et al. Peripheral retinoschisis and exudative retinal detachment in pars planitis. Retina (Philadelphia, Pa). 2002;22(6):719–24.

    Article  Google Scholar 

  123. Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Shukla SY, Reilly B, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol. 2013;131(3):328–34.

    Article  PubMed  Google Scholar 

  124. Pichi F, Srivastava SK, Nucci P, Baynes K, Neri P, Lowder CY. Peripheral retinoschisis in intermediate uveitis. Retina (Philadelphia, Pa). 2017;37(11):2167–74.

    Article  Google Scholar 

  125. Jalil A, Dhawahir-Scala FE, Jones NP. Nonprogressive tractional inferior retinal elevation in intermediate uveitis. Ocul Immunol Inflamm. 2010;18(1):60–3.

    Article  CAS  PubMed  Google Scholar 

  126. Malalis JF, Bhat P, Shapiro M, Goldstein DA. Retinoschisis in pars planitis. Ocul Immunol Inflamm. 2017;25(3):344–8.

    Article  PubMed  Google Scholar 

  127. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013;120(8):1571–9.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Abasolo L, Prieto-Garcia A, Diaz-Valle D, Benitez-Del-Castillo JM, Pato E, Garcia-Feijoo J, et al. Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. Br J Ophthalmol. 2016;100(12):1651–5.

    Article  PubMed  Google Scholar 

  129. Borrego-Sanz L, Abasolo L, Lopez-Abad C, Fernandez-Gutierrez B, Garcia-Feijoo J, Diaz-Valle D, et al. Disease remission in children and adolescents with intermediate uveitis: a survival analysis. Ophthalmologica. 2018;239(2–3):151–8.

    Article  PubMed  Google Scholar 

  130. Holland GN. The enigma of pars planitis, revisited. Am J Ophthalmol. 2006;141(4):729–30.

    Article  PubMed  Google Scholar 

  131. Murphy CC, Hughes EH, Frost NA, Dick AD. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol. 2005;89(9):1161–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Travers C, et al. The association of race with childhood uveitis. Am J Ophthalmol. 2015;160(5):919–28.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Khairallah M, Hmidi K, Attia S, Jelliti B, Hasnaoui W, Zaouali S, et al. Clinical characteristics of intermediate uveitis in Tunisian patients. Int Ophthalmol. 2010;30(5):531–7.

    Article  PubMed  Google Scholar 

  134. Choi DE, Birnbaum AD, Oh F, Tessler HH, Goldstein DA. Pediatric uveitis secondary to probable, presumed, and biopsy-proven sarcoidosis. J Pediatr Ophthalmol Strabismus. 2011;48(3):157–62.

    Article  PubMed  Google Scholar 

  135. Shoughy SS, Kozak I, Tabbara KF. Associations of systemic diseases with intermediate uveitis. Ophthalmic Epidemiol. 2016;23(1):27–31.

    Article  PubMed  Google Scholar 

  136. Gillespie SH, Dinning WJ, Voller A, Crowcroft NS. The spectrum of ocular toxocariasis. Eye (Lond). 1993;7(Pt 3):415–8.

    Article  Google Scholar 

  137. Winward KE, Smith JL, Culbertson WW, Paris-Hamelin A. Ocular Lyme borreliosis. Am J Ophthalmol. 1989;108(6):651–7.

    Article  CAS  PubMed  Google Scholar 

  138. Heinz C, Schoonbrood S, Heiligenhaus A. Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome. Br J Ophthalmol. 2014;98(8):1107–11.

    Article  PubMed  Google Scholar 

  139. Yoshimura K, Shimada N, Shirao M, Mochizuki M, Araki S, Miyata N, et al. [Uveitis in human T-lymphotropic virus type I (HTLV-I) carriers--2. An analysis of clinical features]. Nippon Ganka Gakkai Zasshi. 1993;97(6):733–40.

    Google Scholar 

  140. Soheilian M, Markomichelakis N, Foster CS. Intermediate uveitis and retinal vasculitis as manifestations of cat scratch disease. Am J Ophthalmol. 1996;122(4):582–4.

    Article  CAS  PubMed  Google Scholar 

  141. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102(3):297–301.

    Article  CAS  PubMed  Google Scholar 

  142. Rizzato G, Palmieri G, Agrati AM, Zanussi C. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(2):119–26.

    PubMed  Google Scholar 

  143. Kaiser PK, Lowder CY, Sullivan P, Sanislo SR, Kosmorsky GS, Meziane MA, et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol. 2002;133(4):499–505.

    Article  PubMed  Google Scholar 

  144. Adan A, Baget M, De Llobet JM, Segura A, Marieges MT, Casaroli-Marano R. [Uveitis as initial manifestation of sarcoidosis: study of 31 patients]. Med Clin. 2004;122(19):748–52.

    Google Scholar 

  145. Abad S, Meyssonier V, Allali J, Gouya H, Giraudet AL, Monnet D, et al. Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients. Arthritis Rheum. 2004;51(6):974–82.

    Article  CAS  PubMed  Google Scholar 

  146. Hughes EH, Dick AD. The pathology and pathogenesis of retinal vasculitis. Neuropathol Appl Neurobiol. 2003;29(4):325–40.

    Article  CAS  PubMed  Google Scholar 

  147. Desai UR, Tawansy KA, Joondeph BC, Schiffman RM. Choroidal granulomas in systemic sarcoidosis. Retina (Philadelphia, Pa). 2001;21(1):40–7.

    Article  CAS  Google Scholar 

  148. Vidovic T, Cerovski B, Jukic T. The appearance of pars planitis in multiple sclerosis. Coll Antropol. 2005;29(1):203–6.

    PubMed  Google Scholar 

  149. Messenger W, Hildebrandt L, Mackensen F, Suhler E, Becker M, Rosenbaum JT. Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol. 2015;99(2):205–9.

    Article  PubMed  Google Scholar 

  150. Koga T, Ando E, Hirata A, Fukushima M, Kimura A, Ando Y, et al. Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy. Am J Ophthalmol. 2003;135(2):188–93.

    Article  PubMed  Google Scholar 

  151. Vela JI, Marcantonio I, Diaz-Cascajosa J, Crespi J, Buil JA. Progression of retinal pigmentation mimicking unilateral retinitis pigmentosa after bilateral pars planitis: a case report. BMC Ophthalmol. 2018;18(1):242.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Murro V, Mucciolo DP, Sodi A, Vannozzi L, De Libero C, Simonini G, et al. Retinal capillaritis in a CRB1-associated retinal dystrophy. Ophthalmic Genet. 2017;38(6):555–8.

    Article  CAS  PubMed  Google Scholar 

  153. Verhagen F, Kuiper J, Nierkens S, Imhof SM, Radstake T, de Boer J. Systemic inflammatory immune signatures in a patient with CRB1 linked retinal dystrophy. Expert Rev Clin Immunol. 2016;12(12):1359–62.

    Article  CAS  PubMed  Google Scholar 

  154. Hettinga YM, van Genderen MM, Wieringa W, Ossewaarde-van Norel J, de Boer JH. Retinal dystrophy in 6 young patients who presented with intermediate uveitis. Ophthalmology. 2016;123(9):2043–6.

    Article  PubMed  Google Scholar 

  155. Dutta Majumder P, Menia N, Roy R, Sen P, George AE, Ganesh SK, et al. Uveitis in patients with retinitis pigmentosa: 30 years’ consecutive data. Ocul Immunol Inflamm. 2018;26(8):1283–8.

    Article  PubMed  Google Scholar 

  156. Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. 1966. Retina (Philadelphia, Pa). 2003;23(6 Suppl):646–61.

    CAS  Google Scholar 

  157. Ormerod LD, Puklin JE, Giles CL. Chronic Propionibacterium acnes endophthalmitis as a cause of intermediate uveitis. Ocul Immunol Inflamm. 1997;5(1):67–8.

    Article  CAS  PubMed  Google Scholar 

  158. Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol. 2005;140(5):822–9.

    Article  PubMed  Google Scholar 

  159. Politis M, Rosin B, Amer R. Ocular siderosis subsequent to a missed pars plana metallic foreign body that masqueraded as refractory intermediate uveitis. Ocul Immunol Inflamm. 2018;26(4):598–600.

    PubMed  Google Scholar 

  160. Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond). 2013;27(2):153–62.

    Article  CAS  Google Scholar 

  161. Mruthyunjaya P, Jumper JM, McCallum R, Patel DJ, Cox TA, Jaffe GJ. Diagnostic yield of vitrectomy in eyes with suspected posterior segment infection or malignancy. Ophthalmology. 2002;109(6):1123–9.

    Article  PubMed  Google Scholar 

  162. Seve P, Cacoub P, Bodaghi B, Trad S, Sellam J, Bellocq D, et al. Uveitis: diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmun Rev. 2017;16(12):1254–64.

    Article  PubMed  Google Scholar 

  163. Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology. 2000;107(12):2250–5.

    Article  CAS  PubMed  Google Scholar 

  164. Zaldivar RA, Michels M, Grant KF, Clark WL, Grossniklaus HE. Metastatic breast carcinoma to the vitreous. Retina (Philadelphia, Pa). 2004;24(2):226–30.

    Article  Google Scholar 

  165. Poindron V, Camuset G, Krencker D, Ballonzoli L, Naoun OK, Kennel N, et al. Intermediate uveitis, an ophthalmological manifestation of systemic disease. J Fr Ophtalmol. 2013;36(4):331–5.

    Article  CAS  PubMed  Google Scholar 

  166. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54–8.

    Article  CAS  PubMed  Google Scholar 

  167. Gentile RC, Berinstein DM, Liebmann J, Rosen R, Stegman Z, Tello C, et al. High-resolution ultrasound biomicroscopy of the pars plana and peripheral retina. Ophthalmology. 1998;105(3):478–84.

    Article  CAS  PubMed  Google Scholar 

  168. Tran VT, LeHoang P, Herbort CP. Value of high-frequency ultrasound biomicroscopy in uveitis. Eye (Lond). 2001;15(Pt 1):23–30.

    Article  CAS  Google Scholar 

  169. Greiner KH, Kilmartin DJ, Forrester JV, Atta HR. Grading of pars planitis by ultrasound biomicroscopy--echographic and clinical study. Eur J Ultrasound. 2002;15(3):139–44.

    Article  PubMed  Google Scholar 

  170. Nozik RA. Periocular injection of steroids. Trans Am Acad Ophthalmol Otolaryngol. 1972;76(3):695–705.

    CAS  PubMed  Google Scholar 

  171. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol. 1987;103(3 Pt 1):281–8.

    CAS  PubMed  Google Scholar 

  172. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004;32(6):563–8.

    Article  PubMed  Google Scholar 

  173. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120(1):55–64.

    Article  CAS  PubMed  Google Scholar 

  174. Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(3):441–448.e2.

    Article  CAS  PubMed  Google Scholar 

  175. Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257–63.

    CAS  PubMed  Google Scholar 

  176. Duguid IG, Ford RL, Horgan SE, Towler HM, Lightman SL. Combined orbital floor betamethasone and depot methylprednisolone in uveitis. Ocul Immunol Inflamm. 2005;13(1):19–24.

    CAS  PubMed  Google Scholar 

  177. Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126(2):283–95.

    PubMed  Google Scholar 

  178. Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–86.

    PubMed  PubMed Central  Google Scholar 

  179. Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection. Am J Ophthalmol. 1976;82(6):928–30.

    CAS  PubMed  Google Scholar 

  180. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218–45.

    CAS  PubMed  Google Scholar 

  181. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14(2):73–85.

    PubMed  Google Scholar 

  182. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1–7.

    Google Scholar 

  183. Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ, et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand. 2005;83(5):595–9.

    CAS  PubMed  Google Scholar 

  184. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina (Philadelphia, Pa). 2008;28(1):41–5.

    Google Scholar 

  185. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53.

    PubMed  Google Scholar 

  186. Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–10.

    PubMed  Google Scholar 

  187. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550–561.e10.

    CAS  PubMed  Google Scholar 

  188. Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967–75.

    PubMed  Google Scholar 

  189. Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, et al. Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology. 2015;122(11):2351–9.

    PubMed  PubMed Central  Google Scholar 

  190. Sugar EA, Venugopal V, Thorne JE, Frick KD, Holland GN, Wang RC, et al. Longitudinal vision-related quality of life for patients with noninfectious uveitis treated with fluocinolone acetonide implant or systemic corticosteroid therapy. Ophthalmology. 2017;124(11):1662–9.

    PubMed  PubMed Central  Google Scholar 

  191. Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993–2005.

    CAS  PubMed  PubMed Central  Google Scholar 

  192. Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol (Auckland, NZ). 2009;3:41–7.

    CAS  Google Scholar 

  193. Parekh A, Srivastava S, Bena J, Albini T, Nguyen QD, Goldstein DA. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015;133(5):568–73.

    PubMed  Google Scholar 

  194. Daniel E, Pistilli M, Kothari S, Khachatryan N, Kacmaz RO, Gangaputra SS, et al. Risk of ocular hypertension in adults with noninfectious uveitis. Ophthalmology. 2017;124(8):1196–208.

    PubMed  PubMed Central  Google Scholar 

  195. Itty S, Callanan D, Jones R, Pecen P, Martel J, Jaffe GJ. Spontaneous dislocation of fluocinolone acetonide implant pellets from their suture struts. Am J Ophthalmol. 2015;159(5):868–76.e1.

    CAS  PubMed  Google Scholar 

  196. Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, et al. Dissociations of the fluocinolone acetonide implant: the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Am J Ophthalmol. 2016;164:29–36.

    CAS  PubMed  Google Scholar 

  197. Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, Elner SG, et al. Cataract surgery outcomes in uveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2016;123(1):183–90.

    PubMed  Google Scholar 

  198. Aaberg TM, Cesarz TJ, Flickinger RR Jr. Treatment of pars planitis. I. Cryotherapy. Surv Ophthalmol. 1977;22(2):120–5.

    CAS  PubMed  Google Scholar 

  199. Josephberg RG, Kanter ED, Jaffee RM. A fluorescein angiographic study of patients with pars planitis and peripheral exudation (snowbanking) before and after cryopexy. Ophthalmology. 1994;101(7):1262–6.

    CAS  PubMed  Google Scholar 

  200. Devenyi RG, Mieler WF, Lambrou FH, Will BR, Aaberg TM. Cryopexy of the vitreous base in the management of peripheral uveitis. Am J Ophthalmol. 1988;106(2):135–8.

    CAS  PubMed  Google Scholar 

  201. Sohn EH, Chaon BC, Jabs DA, Folk JC. Peripheral cryoablation for treatment of active pars planitis: long-term outcomes of a retrospective study. Am J Ophthalmol. 2016;162:35–42.e2.

    PubMed  Google Scholar 

  202. Okinami S, Sunakawa M, Arai I, Iwaki M, Nihira M, Ogino N. Treatment of pars planitis with cryotherapy. Ophthalmologica. 1991;202(4):180–6.

    CAS  PubMed  Google Scholar 

  203. Park SE, Mieler WF, Pulido JS. 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch Ophthalmol. 1995;113(10):1277–80.

    CAS  PubMed  Google Scholar 

  204. Pulido JS, Mieler WF, Walton D, Kuhn E, Postel E, Hartz A, et al. Results of peripheral laser photocoagulation in pars planitis. Trans Am Ophthalmol Soc. 1998;96:127–37; discussion 37–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  205. Gonzalez Rubio-Medina E, Pedroza-Seres M. [Clinical course of pars planitis in patients treated with selective photocoagulation]. Arch Soc Esp Oftalmol. 2013;88(8):298–301.

    Google Scholar 

  206. Sizmaz S, Gungor SG, Bayar SA, Yilmaz G, Akkoyun I. Laser photocoagulation in intermediate uveitis associated with retinoschisis. Ocul Immunol Inflamm. 2012;20(5):372–4.

    PubMed  Google Scholar 

  207. Balasubramaniam SC, Mohney BG, Bang GM, Link TP, Pulido JS. Utility of large spot binocular indirect laser delivery for peripheral photocoagulation therapy in children. Arch Ophthalmol. 2012;130(9):1213–7.

    PubMed  Google Scholar 

  208. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140(6):1096–105.

    PubMed  Google Scholar 

  209. Henry CR, Becker MD, Yang Y, Davis JL. Pars plana vitrectomy for the treatment of uveitis. Am J Ophthalmol. 2018;190:142–9.

    PubMed  Google Scholar 

  210. Dev S, Mieler WF, Pulido JS, Mittra RA. Visual outcomes after pars plana vitrectomy for epiretinal membranes associated with pars planitis. Ophthalmology. 1999;106(6):1086–90.

    Article  CAS  PubMed  Google Scholar 

  211. Heimann K, Schmanke L, Brunner R, Amerian B. Pars plana vitrectomy in the treatment of chronic uveitis. Dev Ophthalmol. 1992;23:196–203.

    Article  CAS  PubMed  Google Scholar 

  212. Eckardt C, Bacskulin A. Vitrectomy in intermediate uveitis. Dev Ophthalmol. 1992;23:232–8.

    Article  CAS  PubMed  Google Scholar 

  213. Kroll P, Romstock F, Grenzebach UH, Wiegand W. [Early vitrectomy in endogenous juvenile uveitis intermedia–a long-term study]. Klin Monbl Augenheilkd. 1995;206(4):246–9.

    Google Scholar 

  214. Stavrou P, Baltatzis S, Letko E, Samson CM, Christen W, Foster CS. Pars plana vitrectomy in patients with intermediate uveitis. Ocul Immunol Inflamm. 2001;9(3):141–51.

    Article  CAS  PubMed  Google Scholar 

  215. Trittibach P, Koerner F, Sarra GM, Garweg JG. Vitrectomy for juvenile uveitis: prognostic factors for the long-term functional outcome. Eye (Lond). 2006;20(2):184–90.

    Article  CAS  Google Scholar 

  216. Darsova D, Pochop P, Stepankova J, Dotrelova D. Long-term results of pars plana vitrectomy as an anti-inflammatory therapy of pediatric intermediate uveitis resistant to standard medical treatment. Eur J Ophthalmol. 2018;28(1):98–102.

    Article  PubMed  Google Scholar 

  217. Giuliari GP, Chang PY, Thakuria P, Hinkle DM, Foster CS. Pars plana vitrectomy in the management of paediatric uveitis: the Massachusetts Eye Research and Surgery Institution experience. Eye (Lond). 2010;24(1):7–13.

    Article  CAS  Google Scholar 

  218. Figueroa MS, Noval S, Contreras I, Arruabarrena C, Garcia-Perez JL, Sales M, et al. [Pars plana vitrectomy as anti-inflammatory therapy for intermediate uveitis in children]. Arch Soc Esp Oftalmol. 2010;85(12):390–4.

    Google Scholar 

  219. Wiechens B, Nolle B, Reichelt JA. Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol. 2001;239(7):474–81.

    Article  CAS  PubMed  Google Scholar 

  220. Kaplan HJ. Surgical treatment of intermediate uveitis. Dev Ophthalmol. 1992;23:185–9.

    Article  CAS  PubMed  Google Scholar 

  221. Sato T, Kinoshita R, Taguchi M, Sugita S, Kaburaki T, Sakurai Y, et al. Assessment of diagnostic and therapeutic vitrectomy for vitreous opacity associated with uveitis with various etiologies. Medicine. 2018;97(2):e9491.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Quinones K, Choi JY, Yilmaz T, Kafkala C, Letko E, Foster CS. Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: a prospective, randomized pilot study. Ocul Immunol Inflamm. 2010;18(5):411–7.

    Article  PubMed  Google Scholar 

  223. Harper SL, Foster CS. Intraocular lens explantation in uveitis. Int Ophthalmol Clin. 2000;40(1):107–16.

    Article  CAS  PubMed  Google Scholar 

  224. Estafanous MF, Lowder CY, Meisler DM, Chauhan R. Phacoemulsification cataract extraction and posterior chamber lens implantation in patients with uveitis. Am J Ophthalmol. 2001;131(5):620–5.

    Article  CAS  PubMed  Google Scholar 

  225. Michelson JB, Friedlaender MH, Nozik RA. Lens implant surgery in pars planitis. Ophthalmology. 1990;97(8):1023–6.

    Article  CAS  PubMed  Google Scholar 

  226. Serna-Ojeda JC, Pedroza-Seres M. Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico. Br J Ophthalmol. 2014;98(11):1503–7.

    Article  PubMed  Google Scholar 

  227. Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018;125(2):193–202.

    Article  PubMed  Google Scholar 

  228. Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, et al. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology. 2014;121(10):1855–62.

    Article  PubMed  PubMed Central  Google Scholar 

  229. Squires H, Poku E, Bermejo I, Cooper K, Stevens J, Hamilton J, et al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol Assess (Winchester, Engl). 2017;21(68):1–170.

    Article  Google Scholar 

  230. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brezin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5):757–73.

    Article  PubMed  Google Scholar 

  231. Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology. 1996;103(5):768–75.

    Article  CAS  PubMed  Google Scholar 

  232. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000;342(12):851–9.

    Article  CAS  PubMed  Google Scholar 

  233. Hersh AO, Cope S, Bohnsack JF, Shakoor A, Vitale AT. Use of immunosuppressive medications for treatment of pediatric intermediate uveitis. Ocul Immunol Inflamm. 2018;26(4):642–50.

    CAS  PubMed  Google Scholar 

  234. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.

    Article  CAS  PubMed  Google Scholar 

  235. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335–51.

    Article  CAS  PubMed  Google Scholar 

  236. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104(2):236–44.

    Article  CAS  PubMed  Google Scholar 

  237. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005;89(7):806–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  238. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  239. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.e2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  240. Booth RA, Ansari MT, Tricco AC, Loit E, Weeks L, Doucette S, et al. Assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs. Evid Rep Technol Assess. 2010;196:1–282.

    Google Scholar 

  241. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110(5):1061–5.

    Article  PubMed  Google Scholar 

  242. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112(8):1472–7.

    Article  PubMed  Google Scholar 

  243. Ali S, Kharel Sitaula R, Biswas J. Efficacy and safety of mycophenolate mofetil in the treatment of recalcitrant intermediate uveitis. Ocul Immunol Inflamm. 2018;27:851–7.

    Article  PubMed  CAS  Google Scholar 

  244. Browne EN, Rathinam SR, Kanakath A, Thundikandy R, Babu M, Lietman TM, et al. A Bayesian analysis of a randomized clinical trial comparing antimetabolite therapies for non-infectious uveitis. Ophthalmic Epidemiol. 2017;24(1):63–70.

    Article  PubMed  Google Scholar 

  245. Rathinam SR, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–70.

    Article  PubMed  PubMed Central  Google Scholar 

  246. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm. 1998;6(2):101–9.

    Article  CAS  PubMed  Google Scholar 

  247. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105(11):2028–34.

    Article  CAS  PubMed  Google Scholar 

  248. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–41.

    Article  CAS  PubMed  Google Scholar 

  249. Touhami S, Diwo E, Seve P, Trad S, Bielefeld P, Sene D, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477–90.

    Article  CAS  PubMed  Google Scholar 

  250. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.

    Article  PubMed  Google Scholar 

  251. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–50.

    Article  CAS  PubMed  Google Scholar 

  252. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308–14.

    Article  PubMed  Google Scholar 

  253. Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, et al. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):801–8.

    Article  CAS  PubMed  Google Scholar 

  254. Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, et al. Long-term efficacy and tolerability of TNFalpha inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2019.https://doi.org/10.1136/bjophthalmol-2018-312767

  255. Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27(1):40–50.

    Article  CAS  PubMed  Google Scholar 

  256. Suhler EB, Adan A, Brezin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–87.

    Article  PubMed  Google Scholar 

  257. Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–43.

    Article  CAS  PubMed  Google Scholar 

  258. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481–6.

    Article  PubMed  Google Scholar 

  259. Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405–12.

    Article  CAS  PubMed  Google Scholar 

  260. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–92.

    Article  CAS  PubMed  Google Scholar 

  261. Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511–8.

    Article  PubMed  PubMed Central  Google Scholar 

  262. Becker MD, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89(10):1254–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  263. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–35.

    Article  CAS  PubMed  Google Scholar 

  264. Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–13.

    Article  CAS  PubMed  Google Scholar 

  265. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.

    Article  CAS  PubMed  Google Scholar 

  266. Vegas-Revenga N, Calvo-Rio V, Mesquida M, Adan A, Hernandez MV, Beltran E, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious Uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94.

    Article  CAS  PubMed  Google Scholar 

  267. Belfort R Jr, de Abreu MT, Petrilli AM, Kim MK, Martins MC, Lottemberg C, et al. Cytotoxic drugs in intermediate uveitis. Dev Ophthalmol. 1992;23:171–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Janet L. Davis

Authors
  1. Janet L. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet L. Davis .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Oregon Health & Science University Department of Ophthalmology, Portland, OR, USA

    Daniel Albert

  2. Massachusetts Eye and Ear, Boston, MA, USA

    Joan Miller

  3. Department of Ophthalmology, University of Illinois at Chicago Department of Ophthalmology, Chicago, IL, USA

    Dimitri Azar

  4. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA

    Lucia Sobrin

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Davis, J.L. (2020). Intermediate Uveitis. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_13-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90495-5_13-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90495-5

  • Online ISBN: 978-3-319-90495-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation